Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Phase III Study of Trastuzumab-Docetaxel vs Trastuzumab-Vinorelbine as 1. Line Therapy for Patients With Metastatic HER2 Positive Breast Cancer

NCT00430001 is registered in ClinicalTrials.gov with Danish Breast Cancer Cooperative Group as lead sponsor.

NCT NCT00430001
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00430001 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Phase III Study of Trastuzumab-Docetaxel vs Trastuzumab-Vinorelbine as 1. Line Therapy for Patients With Metastatic HER2 Positive Breast Cancer
Lead sponsor
Danish Breast Cancer Cooperative Group
Phase
Phase 3
Overall status
Unknown status
Start date
May 31, 2005
Completion date
December 31, 2008
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer